Q3 EPS Estimates for XOMA Royalty Lifted by HC Wainwright

XOMA Royalty Corporation (NASDAQ:XOMA) – Equities researchers at HC Wainwright lifted their Q3 2025 EPS estimates for shares of XOMA Royalty in a research note issued on Thursday, August 21st. HC Wainwright analyst J. Pantginis now forecasts that the biotechnology company will earn $0.21 per share for the quarter, up from their prior forecast of $0.03. HC Wainwright has a “Buy” rating and a $104.00 price target on the stock. The consensus estimate for XOMA Royalty’s current full-year earnings is ($1.41) per share. HC Wainwright also issued estimates for XOMA Royalty’s Q4 2025 earnings at $0.24 EPS and FY2025 earnings at $1.17 EPS.

XOMA Royalty (NASDAQ:XOMA) last announced its earnings results on Wednesday, August 13th. The biotechnology company reported $0.48 EPS for the quarter, topping the consensus estimate of ($0.12) by $0.60. XOMA Royalty had a negative net margin of 27.57% and a positive return on equity of 2.63%. The company had revenue of $13.13 million during the quarter, compared to analysts’ expectations of $9.39 million.

A number of other analysts have also issued reports on the stock. Zacks Research raised shares of XOMA Royalty to a “hold” rating in a research report on Tuesday, August 12th. Wall Street Zen raised shares of XOMA Royalty from a “hold” rating to a “buy” rating in a research report on Monday, August 11th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $69.50.

XOMA Royalty Stock Performance

Shares of XOMA opened at $34.20 on Monday. XOMA Royalty has a one year low of $18.35 and a one year high of $35.00. The company has a 50-day moving average of $27.20 and a two-hundred day moving average of $24.55. The stock has a market cap of $413.48 million, a price-to-earnings ratio of -22.06 and a beta of 1.00. The company has a debt-to-equity ratio of 1.41, a current ratio of 4.88 and a quick ratio of 4.88.

Hedge Funds Weigh In On XOMA Royalty

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC raised its position in XOMA Royalty by 1,063.8% during the first quarter. GAMMA Investing LLC now owns 1,734 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 1,585 shares in the last quarter. Nuveen Asset Management LLC raised its position in shares of XOMA Royalty by 3.8% in the fourth quarter. Nuveen Asset Management LLC now owns 14,363 shares of the biotechnology company’s stock valued at $377,000 after purchasing an additional 527 shares during the period. Northern Trust Corp raised its position in shares of XOMA Royalty by 1.5% in the fourth quarter. Northern Trust Corp now owns 91,181 shares of the biotechnology company’s stock valued at $2,396,000 after purchasing an additional 1,340 shares during the period. Bank of America Corp DE raised its position in shares of XOMA Royalty by 34.7% in the fourth quarter. Bank of America Corp DE now owns 7,796 shares of the biotechnology company’s stock valued at $205,000 after purchasing an additional 2,009 shares during the period. Finally, Renaissance Technologies LLC raised its position in shares of XOMA Royalty by 89.8% in the fourth quarter. Renaissance Technologies LLC now owns 16,100 shares of the biotechnology company’s stock valued at $423,000 after purchasing an additional 7,619 shares during the period. Institutional investors own 95.92% of the company’s stock.

About XOMA Royalty

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.